Rosario Pivonello

Rosario Pivonello's AcademicInfluence.com Rankings

Rosario Pivonello

Biology

#10801

World Rank

#14158

Historical Rank

Endocrinology

#150

World Rank

#162

Historical Rank

Biotechnology

#167

World Rank

#169

Historical Rank

Molecular Biology

#1610

World Rank

#1638

Historical Rank

biology Degrees

Download Badge

Biology

Rosario Pivonello's Degrees

PhD Biomedical Sciences University of Naples Federico II
Masters Biotechnology University of Naples Federico II
Bachelors Biotechnology University of Naples Federico II

Why Is Rosario Pivonello Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Rosario Pivonello's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. (1999) (432)
Complications of Cushing's syndrome: state of the art. (2016) (306)
Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. (2003) (304)
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. (2009) (292)
Dopamine receptor expression and function in corticotroph pituitary tumors. (2004) (256)
Resistance to somatostatin analogs in acromegaly. (2011) (221)
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. (2000) (216)
Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. (1999) (212)
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. (2003) (207)
The Treatment of Cushing's Disease. (2015) (202)
Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. (2008) (202)
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. (2006) (191)
Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism (2016) (189)
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. (2001) (183)
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia (2003) (181)
Predictors of morbidity and mortality in acromegaly: an Italian survey. (2012) (175)
Medical therapy for clinically non-functioning pituitary adenomas. (2008) (164)
Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. (1997) (157)
The metabolic syndrome and cardiovascular risk in Cushing's syndrome. (2005) (155)
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. (2006) (153)
LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. (2014) (152)
Novel insights in dopamine receptor physiology. (2007) (149)
Pathophysiology of Diabetes Mellitus in Cushing’s Syndrome (2010) (148)
Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. (2001) (147)
The environment and male reproduction: The effect of cadmium exposure on reproductive function and its implication in fertility. (2017) (147)
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities (2017) (144)
Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. (2008) (141)
Consensus on diagnosis and management of Cushing's disease: a guideline update. (2021) (138)
Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. (2001) (133)
Dopamine receptor agonists for treating prolactinomas (2002) (128)
Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. (2009) (128)
Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. (2001) (128)
High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. (2003) (128)
Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. (2006) (125)
Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. (2017) (125)
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. (2006) (125)
Increased arterial intima‐media thickness by B‐M mode echodoppler ultrasonography in acromegaly (2001) (124)
Cushing’s disease: the burden of illness (2017) (123)
Smoke, alcohol and drug addiction and male fertility (2018) (122)
Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis (2021) (122)
The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. (2002) (118)
Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. (2005) (117)
Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. (2004) (116)
Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. (2008) (115)
Prolactin and Autoimmunity (2005) (113)
Acromegaly (2019) (112)
Early vascular alterations in acromegaly. (2002) (112)
Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. (1998) (111)
Hypertension in acromegaly and in the normal population: prevalence and determinants (2005) (111)
The dexamethasone‐suppressed corticotropin‐releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo‐Cushing's states (2007) (111)
The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications (2015) (110)
Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study (2003) (109)
Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. (2003) (109)
Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease (2015) (109)
Reversal of acromegalic cardiomyopathy in young but not in middle‐aged patients after 12 months of treatment with the depot long‐acting somatostatin analogue octreotide (2003) (106)
COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency (2020) (101)
The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. (1999) (98)
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. (2018) (96)
Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. (2015) (96)
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study (2014) (95)
Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. (2004) (94)
The heart: an end-organ of GH action. (2004) (93)
Cardiovascular consequences of early-onset growth hormone excess. (2002) (91)
Predictors of remission of hyperprolactinaemia after long‐term withdrawal of cabergoline therapy (2007) (91)
Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. (1996) (91)
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas (2000) (91)
Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure. (2003) (89)
Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization (2000) (89)
Air pollution and female fertility: a systematic review of literature (2018) (87)
Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. (2008) (86)
Cabergoline plus lanreotide for ectopic Cushing's syndrome. (2005) (85)
Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients (2004) (85)
Cardiovascular Disease in Cushing’s Syndrome: Heart versus Vasculature (2010) (85)
SARS-CoV-2 infection, male fertility and sperm cryopreservation: a position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) (Società Italiana di Andrologia e Medicina della Sessualità) (2020) (85)
Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. (1999) (85)
Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease (1998) (85)
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly (2015) (84)
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. (2008) (79)
Bisphenol A: an emerging threat to female fertility (2020) (79)
Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. (2007) (79)
Shedding new light on female fertility: The role of vitamin D (2017) (79)
Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. (2004) (79)
Acromegaly and the Cardiovascular System (2006) (78)
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. (2007) (78)
First‐line octreotide‐LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial (2006) (77)
Cushing's Syndrome. (2008) (76)
Severe impairment of bone mass and turnover in Cushing’s disease: comparison between childhood‐onset and adulthood‐onset disease (2002) (76)
Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. (2003) (76)
Neuropsychiatric disorders in Cushing's syndrome (2015) (74)
Cushing's syndrome: aftermath of the cure. (2007) (73)
Acromegalic axial arthropathy: a clinical case-control study. (2004) (73)
Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. (2002) (71)
Influence of Bisphenol A on Type 2 Diabetes Mellitus (2016) (71)
Advances in the medical treatment of Cushing's syndrome. (2019) (71)
Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. (2013) (71)
The role of inferior petrosal sinus sampling in ACTH-dependent Cushing's syndrome: review and joint opinion statement by members of the Italian Society for Endocrinology, Italian Society for Neurosurgery, and Italian Society for Neuroradiology. (2015) (71)
Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age (2005) (70)
Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. (2013) (70)
Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline (1999) (70)
Dopamine receptor expression and function in corticotroph ectopic tumors. (2007) (70)
Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature (2012) (67)
The role of vitamin D in male fertility: A focus on the testis (2017) (66)
The cardiovascular system in growth hormone excess and growth hormone deficiency (2012) (66)
Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. (2011) (66)
Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. (2003) (65)
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly (1999) (64)
NT-proBNP, IGF-I and survival in patients with chronic heart failure. (2007) (64)
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly (2015) (64)
Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. (2007) (62)
Significant tumour shrinkage after 12 months of lanreotide Autogel‐120 mg treatment given first‐line in acromegaly (2009) (62)
A longitudinal study of vasopressin cell antibodies, posterior pituitary function, and magnetic resonance imaging evaluations in subclinical autoimmune central diabetes insipidus. (1999) (61)
Longitudinal study of vasopressin-cell antibodies and of hypothalamic-pituitary region on magnetic resonance imaging in patients with autoimmune and idiopathic complete central diabetes insipidus. (2002) (60)
Therapy of aggressive pituitary tumors (2011) (60)
The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. (2007) (58)
Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. (2009) (58)
Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. (2005) (58)
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. (2013) (57)
Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? (2014) (57)
Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger? (2020) (56)
The metabolic profile in active acromegaly is gender-specific. (2013) (56)
Metabolic Disorders and Male Hypogonadotropic Hypogonadism (2019) (55)
Growth hormone, prolactin, and sexuality (2012) (53)
Acromegaly is associated with increased cancer risk: a survey in Italy. (2017) (53)
Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. (2009) (53)
Investigation of sperm telomere length as a potential marker of paternal genome integrity and semen quality. (2016) (52)
Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. (2007) (51)
Medical therapy of pituitary adenomas: Effects on tumor shrinkage (2009) (51)
Insulin‐like growth factor‐1 deficiency determines increased intima–media thickness at common carotid arteries in adult patients with growth hormone deficiency (2004) (51)
Effect of Cabergoline on Metabolism in Prolactinomas (2013) (51)
Evaluation of the retinal nerve fibre layer and ganglion cell complex thickness in pituitary macroadenomas without optic chiasmal compression (2015) (50)
Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. (2008) (50)
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson’s disease patients (2013) (50)
Pituitary magnetic resonance imaging in Cushing’s disease (2017) (48)
The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. (2012) (47)
Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials (2020) (47)
Pegvisomant in acromegaly: an update (2017) (46)
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. (2019) (46)
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson’s disease (2013) (46)
Lung volumes and respiratory muscle strength in adult patients with childhood- or adult-onset growth hormone deficiency: effect of 12 months' growth hormone replacement therapy. (1996) (46)
Smoke, alcohol and drug addiction and female fertility (2020) (45)
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial (2014) (45)
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline (2014) (45)
Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells (2020) (45)
Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study (2000) (44)
Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection (2020) (43)
Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease (2000) (43)
Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. (1998) (43)
Insulin‐like growth factor‐1 predicts cognitive functions at 2‐year follow‐up in early, drug‐naïve Parkinson's disease (2014) (43)
Circadian Rhythm of Glucocorticoid Administration Entrains Clock Genes in Immune Cells: A DREAM Trial Ancillary Study (2018) (43)
Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. (2010) (43)
The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center (2015) (42)
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly (2006) (42)
Subclinical Cushing's syndrome. (2012) (41)
The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. (2010) (41)
Cardiovascular complications in acromegaly. (2004) (41)
The pituitary uptake of 111In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas (1999) (41)
Six controversial issues on subclinical Cushing’s syndrome (2017) (40)
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase. (2020) (39)
The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis. (2006) (39)
SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas (2007) (39)
Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of cabergoline treatment (2005) (39)
Association between vitamin D and sperm parameters: Clinical evidence (2017) (38)
Efficacy and safety of osilodrostat in patients with Cushings disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase (2021) (38)
Pegvisomant in acromegaly: Why, when, how (2007) (37)
Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease. (2005) (37)
Expression and Function of Somatostatin Receptor Subtype 1 in Human Growth Hormone Secreting Pituitary Tumors Deriving from Patients Partially Responsive or Resistant to Long-Term Treatment with Somatostatin Analogs (2004) (37)
Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly. (2002) (37)
Role of the mTOR Pathway in Normal and Tumoral Adrenal Cells (2010) (37)
Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I. (2007) (36)
Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass (2004) (35)
Testosterone treatment in male patients with Klinefelter syndrome: a systematic review and meta-analysis (2020) (35)
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study (2012) (34)
Medical consequences of acromegaly: What are the effects of biochemical control? (2008) (34)
Spine Abnormalities and Damage in Patients Cured from Cushing's Disease (2001) (34)
Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas (2003) (34)
Cabergoline use for pituitary tumors and valvular disorders. (2015) (33)
GH and IGF‐I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment (2008) (33)
Cardiovascular Complications in Acromegaly: Methods of Assessment (2001) (33)
Antipituitary Antibodies in Idiopathic Hyperprolactinemic Patients (2007) (32)
Cardiovascular alterations in adult GH deficiency. (2017) (32)
Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. (2010) (32)
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? (2015) (32)
Association of pelvic endometriosis with alopecia universalis, autoimmune thyroiditis and multiple sclerosis (2006) (31)
Failure of long-term therapy with sodium valproate in Cushing’s disease (1997) (31)
Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. (2013) (31)
Risk behaviours and alcohol in adolescence are negatively associated with testicular volume: results from the Amico‐Andrologo survey (2019) (31)
Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion (2019) (31)
Preoperative workup in the assessment of adrenal incidentalomas: outcome from 282 consecutive laparoscopic adrenalectomies (2013) (31)
People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction (2020) (30)
Molecular basis of pharmacological therapy in Cushing’s disease (2014) (30)
Glucocorticoid excess and COVID-19 disease (2020) (30)
Adverse events associated with somatostatin analogs in acromegaly (2015) (30)
Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly (2015) (30)
Impairment of bone status in patients with central diabetes insipidus. (1998) (29)
In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: Correlation with somatostatin and dopamine D2 receptor scintigraphy (2001) (29)
Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. (2012) (29)
Physiological and pathophysiological role of somatostatin receptors in the human thymus. (2000) (29)
Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test (2006) (29)
The acromegalic arthropathy. (2005) (29)
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. (2008) (29)
The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome (2017) (28)
Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). (2014) (28)
Effect of gender and gonadal status on the long‐term response to somatostatin analogue treatment in acromegaly (2005) (28)
The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence” (2019) (28)
Increased IGF‐I : IGFBP‐3 ratio in patients with hepatocellular carcinoma (2003) (28)
Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients. (2003) (28)
Medical therapy of Cushing's disease (2008) (27)
Cardiac Abnormalities in Acromegaly (2004) (27)
Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients (1999) (27)
Cardiac effect of thyrotoxicosis in acromegaly. (2000) (26)
Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess. (2016) (26)
Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head- to- head study (2008) (26)
The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. (2010) (26)
Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status (2014) (26)
A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. (2014) (26)
Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson’s disease (2017) (25)
Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas (2015) (25)
Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late‐onset cerebellar ataxia (2005) (25)
Erectile dysfunction and cardiovascular risk: a review of current findings (2020) (24)
Hypovitaminosis D: a novel risk factor for coronary heart disease in type 2 diabetes? (2016) (24)
Growth hormone excess with onset in adolescence: clinical appearance and long‐term treatment outcome (2007) (24)
Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing’s disease (2002) (24)
Approach to patients with pseudo-Cushing’s states (2019) (24)
Age-related decrease of somatostatin receptor number in the normal human thymus. (2000) (24)
Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas (2019) (23)
The GH–IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin‐like growth factors and clinical features (2010) (23)
Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer (2016) (23)
Erectile Dysfunction is Common among Men with Acromegaly and is Associated with Morbidities Related to the Disease. (2015) (23)
Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. (2016) (23)
Multiple system atrophy is associated with changes in peripheral insulin‐like growth factor system (2010) (23)
Molecular Imaging Targeting Corticotropin Releasing Hormone Receptor for Corticotropinoma: A Changing Paradigm. (2020) (23)
The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets (2014) (22)
Lymphocyte subset pattern in acromegaly (2002) (22)
Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor. (2008) (22)
Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma (2020) (22)
Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. (2014) (22)
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study (2016) (22)
Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy (2012) (22)
Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing’s syndrome (2009) (22)
COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess (2020) (22)
Current management and outcome of pregnancies in women with adrenal insufficiency: experience from a multi-center survey. (2020) (21)
Glycometabolic control in acromegalic patients with diabetes: A study of the effects of different treatments for growth hormone excess and for hyperglycemia (2012) (21)
IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer (2019) (21)
Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? (2013) (21)
Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs (2019) (20)
In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features (2001) (20)
Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency (2010) (20)
The Vaginal Microbiome: A Long Urogenital Colonization Throughout Woman Life (2021) (20)
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma (2016) (20)
P-77 Relationships between serum insulin-like growth factor-I levels, blood pressure and glucose tolerance: an observational, exploratory study in 404 subjects (2008) (19)
The safety of treatments for prolactinomas (2016) (19)
Recombinant FSH Improves Sperm DNA Damage in Male Infertility: A Phase II Clinical Trial (2018) (19)
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease (2019) (19)
The effects of hyperprolactinemia and its control on metabolic diseases (2018) (19)
Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland (2017) (19)
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. (2007) (19)
Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: An open-label, multicenter, non-comparative study (2005) (19)
The study of spontaneous GH secretion after 36‐h fasting distinguishes between GH‐deficient and normal adults (1999) (19)
Selenium supplementation modulates apoptotic processes in thyroid follicular cells (2017) (19)
Patients with Cushing's disease achieve normal urinary cortisol with LCI699, a potent 11[beta]-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study (2012) (18)
Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly (2017) (18)
Impaired Bone Metabolism in Glycogen Storage Disease Type 1 Is Associated with Poor Metabolic Control in Type 1a and with Granulocyte Colony-Stimulating Factor Therapy in Type 1b (2013) (18)
Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation (2015) (18)
Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. (2000) (18)
Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. (2011) (18)
R31C GNRH1 Mutation and Congenital Hypogonadotropic Hypogonadism (2013) (18)
Acromegaly and Heart Failure. (2019) (17)
Pulsed tissue Doppler identifies subclinical myocardial biventricular dysfunction in active acromegaly (2006) (17)
Flavor perception test: evaluation in patients with Kallmann syndrome (2016) (17)
Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. (2006) (16)
Effect of corticotrophin‐releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease (1998) (16)
The effect of FT500 Plus(®) on ovarian stimulation in PCOS women. (2016) (16)
A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients (2007) (16)
Andrological effects of SARS-Cov-2 infection: a systematic review and meta-analysis (2022) (16)
Severe systemic complications of acromegaly. (2005) (16)
Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance (2017) (15)
Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us? (2019) (15)
Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? (2012) (15)
Short stature and azoospermia in a patient with Y chromosome long arm deletion (1997) (15)
Potential indications for somatostatin analogues: immune system and limphoproliferative disorders. (2005) (15)
Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health (2021) (15)
Corticotroph Tumor Progression after Bilateral Adrenalectomy (Nelson's syndrome): Systematic Review and Expert Consensus Recommendations. (2021) (15)
Use of follicle‐stimulating hormone for the male partner of idiopathic infertile couples in Italy: Results from a multicentre, observational, clinical practice survey (2019) (14)
Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM) (2017) (14)
The growth hormone-insulin-like growth factor axis in glycogen storage disease type 1: evidence of different growth patterns and insulin-like growth factor levels in patients with glycogen storage disease type 1a and 1b. (2010) (14)
Effect of long‐term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodies (2008) (14)
Neuropsychiatric Aspects in Men with Klinefelter Syndrome (2019) (14)
Isoform-specific NF1 mRNA levels correlate with disease severity in Neurofibromatosis type 1 (2019) (14)
The treatment with growth hormone receptor antagonist in acromegaly: Effect on vascular structure and function in patients resistant to somatostatin analogues (2010) (13)
Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study (2019) (13)
Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study (2018) (13)
Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. (2010) (13)
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study (2021) (13)
Erratum: The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states (Clinical Endocrinology (2007) 66, (251-257)) (2007) (13)
Treatment of Acromegalic Osteopathy in Real-Life Clinical Practice: The BAAC (Bone Active drugs in ACromegaly) Study. (2020) (13)
The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center (2019) (12)
The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology (2020) (12)
Dopamine Agonists: From the 1970s to Today (2019) (12)
Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas. (2019) (12)
Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome (2020) (12)
Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study (2019) (12)
Testosterone supplementation and bone parameters: a systematic review and meta-analysis study (2022) (11)
Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance (2001) (11)
Long-acting pasireotide improves clinical signs and quality of life in Cushing’s disease: results from a phase III study (2020) (11)
IGF system and peripheral arterial disease: relationship with disease severity and inflammatory status of the affected limb (2008) (11)
Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. (1999) (11)
The glucocorticoid analog dexamethasone alters the expression and the distribution of dopamine receptors and enkephalin within cortico-subcortical regions. (2013) (11)
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit (2019) (11)
The role of somatostatin receptors in the medical treatment of acromegaly. (2004) (11)
Investigational therapies for acromegaly (2013) (11)
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study (2017) (11)
Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. (2000) (10)
Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib (2016) (10)
The diagnosis of secondary adrenal insufficiency: Low dose vs high dose ACTH stimulation test (2003) (10)
The role of mTOR pathway as target for treatment in adrenocortical cancer (2019) (10)
Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study (2021) (10)
Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects (2011) (10)
Quality of life in patients with Cushing's disease: a modern approach (2012) (10)
Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement (2020) (10)
Cushing, acromegaly, GH deficiency and tendons. (2014) (10)
Long-term use of pasireotide in Cushing's disease: 24-month safety results from a randomized phase III study (2012) (9)
The arginine growth hormone stimulation test in bradykinetic‐rigid parkinsonisms (2008) (9)
Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. (2010) (9)
Medical Treatment of Cushing’s Disease with Pasireotide (2010) (9)
A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score (2021) (9)
The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review (2021) (9)
Tumor necrosis factor-alpha increases after corticotropin-releasing hormone administration in Cushing's disease. In vivo and in vitro studies. (1996) (9)
Circulating endothelial progenitor cells in acromegaly (2013) (9)
Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells (2016) (9)
ACTH increment post total bilateral adrenalectomy for Cushing’s disease: a consistent biosignature for predicting Nelson’s syndrome (2020) (9)
Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia (2001) (9)
OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3) (2019) (9)
Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study (2018) (9)
The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. (2003) (8)
Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE) (2022) (8)
Endocrine changes (beyond diabetes) after bariatric surgery in adult life (2013) (8)
Growth Hormone Deficiency in Elderly Patients with Hypothalamo-Pituitary Tumors (1998) (8)
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting (2018) (8)
Bariatric surgery for obesity and hidden Cushing syndrome. (2009) (8)
New perspectives in the medical treatment of acromegaly. (2005) (8)
Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy. (2005) (8)
Possible protective role of metformin therapy on colonic polyps in acromegaly: an exploratory cross-sectional study. (2021) (8)
SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas (2019) (7)
Author Correction: Acromegaly (2019) (7)
Spot-light on microbiota in obesity and cancer (2021) (7)
Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration (2002) (7)
Erratum to: Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib (2017) (6)
Pasireotide treatment is associated with improvements in hypertension: 12-month results from a large phase III study in Cushing's disease (2012) (6)
Effectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing's disease partially responsive to monotherapy with cabergoline (2009) (6)
Mission study: an international observational study on the mortality in Cushing's syndrome (2011) (6)
Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension (2022) (6)
When to suspect hidden hypercortisolism in type 2 diabetes: a meta-analysis. (2021) (6)
Correction: R31C GNRH1 Mutation and Congenital Hypogonadotropic Hypogonadism (2013) (5)
Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant (2022) (5)
Improvement in clinical signs and symptoms of Cushing's disease following 12 months' pasireotide therapy (2011) (5)
Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly (2017) (5)
Exposure to artificial light at night: A common link for obesity and cancer? (2022) (5)
Pasireotide alone or in combination with cabergoline effectively controls urinary free cortisol levels: results from a prospective study in patients with Cushing's disease (CAPACITY) (2017) (5)
Remission in Cushing’s disease is predicted by cortisol burden and its withdrawal following pituitary surgery (2021) (5)
Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies (2017) (5)
The treatment algorithm of acromegaly. (2003) (5)
Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study (2021) (5)
Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life (2022) (5)
Long-term pasireotide use leads to improvements in the biochemical parameters of Cushing's disease: 24-month results from a randomized phase III study (2012) (5)
Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment (2021) (5)
Levoketoconazole: a novel treatment for endogenous Cushing's syndrome (2021) (5)
Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing’s disease before and after corticotropin-releasing hormone administration (1998) (5)
SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database (2020) (5)
Fertility rate in acromegalic women: a single center experience on 70 patients before and after treatment (2011) (4)
Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas (2021) (4)
Cortisol Circadian Rhythm and Insulin Resistance in Muscle: Effect of Dosing and Timing of Hydrocortisone Exposure on Insulin Sensitivity in Synchronized Muscle Cells (2020) (4)
Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study (2021) (4)
Cushing’s disease: adrenal steroidogenesis inhibitors (2022) (4)
The 17β-hydroxysteroid dehydrogenase type 3 deficiency: a case report of an 18-year patient and review of the literature. (2013) (4)
MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study (2020) (3)
Etiology-, Sex-, and Tumor Size-Based Differences in Adrenocorticotropin-Dependent Cushing Syndrome. (2020) (3)
The role of somatostatin analogs in the management of immunoproliferative disease. (2003) (3)
The role of dopamine pathway on human sperm: in vitro effect of dopamine receptor agonists and antagonists on sperm motility, kinetics and viability (2016) (3)
Results from the phase 3 multicenter SONICS study of levoketoconazole: subgroup analysis of Cushing's syndrome patients with diabetes mellitus (2019) (3)
Subclinical male hypogonadism. (2020) (3)
Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS) (2022) (3)
Mortality and morbidity in Cushing's syndrome: a single centre experience (2011) (3)
The dopaminergic control of Cushing’s syndrome (2022) (3)
Cabergoline treatment in Cushings disease: effect on hypertension, glucose intolerance and dyslipidemia. (2007) (3)
Cortisol and the muscle-bone axis: response to comments by Molfino et al. (2015) (3)
Normalization of urinary cortisol with the potent 11[beta]-hydroxylase inhibitor LCI699 in patients with Cushing's disease: 22-week, multicentre, open-label study (2014) (2)
Late-night salivary cortisol (LNSC) levels in a Phase III study of long-acting pasireotide in patients with Cushing's disease (CD) (2018) (2)
Erectile Dysfunction and Decreased Libido in Klinefelter Syndrome: A Prevalence Meta-Analysis and Meta-Regression Study. (2021) (2)
Erratum to: The treatment with pasireotide in Cushing’s disease: effects of long–term treatment on tumor mass in the experience of a single center (2016) (2)
Pasireotide for the treatment of Cushing's disease (2013) (2)
Severe impact of late diagnosis of congenital adrenal hyperplasia on gender identity, sexual orientation and function: case report and review of the literature (2022) (2)
Levoketoconazole in the treatment of endogenous Cushing’s syndrome: Extended evaluation phase results of the SONICS study (2020) (2)
Expression of mTOR pathway in human adrenocortical carcinomas and in vitro effects of mTOR inhibitors in human adrenocortical cell lines (2009) (2)
Potential role of vitamin D in restoring sensitivity to mTOR inhibitors in hepatocellular carcinoma (HCC): 1,25(OH)vitamin D (VitD) reverts everolimus (EVE) resistance in a hcc cell line (2016) (2)
Ketoconazole induces inhibition of cell viability and apoptosis in an ACTH-secreting tumour cell line model (2017) (2)
Hyperprolactinemia after menopause: Diagnosis and management. (2021) (2)
Osilodrostat provides clinical benefit over 48 weeks in patients with Cushing disease: Results from the LINC 3 study (2019) (2)
Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial (2022) (2)
MicroRNAs and Long Non-Coding RNAs in Adrenocortical Carcinoma (2022) (2)
Environmental Factors’ Interference in Endocrine Aspects of Male Reproduction (2020) (2)
Analysis of germline VEGF-A SNPs allows the identification of a subgroup of ATA low-intermediate risk DTC (differentiated thyroid cancer) patients with poor probability to develop recurrences (2016) (2)
How May Obesity-Induced Oxidative Stress Affect the Outcome of COVID-19 Vaccines? Lesson Learned from the Infection (2021) (2)
How should patients with adrenal incidentalomas be followed up? (2014) (2)
Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity (2021) (2)
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence - Authors' reply. (2022) (2)
Vitamin D from genetics to the clinical in prostate cancer (2012) (2)
Long-term (19-month) control of urinary free cortisol with osilodrostat in patients with Cushing's disease: results from an extension to the LINC-2 study (2016) (2)
Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension (2022) (2)
Abstract #1183049: Hypertension (HTN) and Diabetes (DM) Improvement During Osilodrostat Therapy in Patients with Cushing’s Disease (CD): Analyses from the Phase III LINC 3 study (2022) (1)
Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. (2003) (1)
The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets (2014) (1)
Chapter 8 Autoimmunity and the Pituitary Gland (2008) (1)
Sperm Global DNA Methylation (SGDM) in Semen of Healthy Dogs (2021) (1)
Is mortality in Cushing's disease reversible with remission? (2016) (1)
Study Design of a Phase II trial of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease (2014) (1)
Hepatocellular carcinoma (HCC) as a neuroendocrine tumor: a preliminar molecular study. (2012) (1)
Abstract #1040637: Effect of Osilodrostat on Clinical signs, Physical Features and Health-related Quality of Life (HRQoL) by Degree of mUFC Control in Patients with Cushing’s Disease (CD): Results from the LINC3 Study (2021) (1)
Acknowledgement of reviewers 2011 (2012) (1)
Osteoporosis: May Doping Cause It? (2020) (1)
Predictive value of acute cortisol response to cabergoline administration on the responsiveness of cortisol secretion to short and long term treatment with cabergoline (2011) (1)
Cushing syndrome, metabolic syndrome and inflammation: a suggested way out (2013) (1)
Reactivation of Takayasu arteritis in two patients with Cushing's disease after normalization of cortisol secretion. (2012) (1)
Effect of GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in acromegalic patients resistant to somatostatin analogues (2007) (1)
Evaluation of ejaculatory function in acromegalic men: preliminary study (2012) (1)
1,25 dihydroxyvitamin D reverses everolimus resistance in hepatocellular carcinoma activating mesenchymal-epithelial transition and miR-375 (2018) (1)
Uncommon Clinical Course of Multiple Osteochondromatosis in a Patient with a Long-Term History of Cushing's Disease (2001) (1)
The role of somatostatin analogs in the management of hepatocellular carcinoma. (2003) (1)
Effect of chronic treatment with cabergoline and testosterone replacement on metabolic parameters in male patients with prolactinomas and hypogonadism (2014) (1)
Dopamine receptor expression and dopamine agonist effectiveness in corticotroph pituitary tumors: comparison with clinical, biochemical radiological and pathological features of patients with Cushing's disease (2008) (1)
Levoketoconazole treatment in endogenous Cushing’s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes (2022) (1)
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushings syndrome (SONICS): A phase 3, multicentre, open-label, single-arm trial (2020) (1)
Physiopathology, Diagnosis, and Treatment of Hypercortisolism (2018) (1)
Fasting insulin levels are predictors of colonic lesions in patients with acromegaly: an observational, open, prospective study in 189 patients (2007) (1)
Review for "ACE2 in the second act of COVID‐19 syndrome: Peptide dysregulation and possible correction with oestrogen" (2020) (1)
Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors (2011) (1)
Targeting the insulin-like growth factor 1 (IGF1R) and insulin (IR) receptor with a dual IGF1R/IR inhibitor, OSI-906, to potentiate mTOR inhibitor effects in experimental models of hepatocellular carcinoma (HCC) (2014) (1)
Impact of long-term cabergoline treatment on clinical, metabolic and hormonal features in patients with Cushing's syndrome (2011) (1)
Role of somatostatin analogues in the management of immunolymphoproliferative diseases (2003) (1)
Lack of somatostatin analogs effectiveness in gonadotropin-secreting pituitary adenomas: Report of a case and review of the literature (2006) (1)
Evaluation of male sexual function in active acromegalic patients and after disease remission: preliminary study (2012) (1)
Glucose tolerance and somatostatin analogues treatment in acromegaly: a 12 month open, prospective study (2009) (1)
Evaluation of Late-Night Salivary Cortisol during a Phase III Study with Pasireotide in Patients with Cushing's Disease (2013) (1)
Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study (2022) (1)
Cardiac performance after long-term treatment with Pegvisomant in patients with acromegaly: a radionuclide angiography study (2008) (1)
Circulating myomiRNAs as biomarkers of Cushings syndrome (2021) (1)
Osilodrostat is an effective and well-tolerated treatment option for patients with Cushings disease (CD): Final results from the LINC3 study (2021) (1)
Efficacy and tolerability of treatment with pegvisomant in acromegaly: an overview of literature (2015) (1)
Metabolic effects of prolactin (2022) (1)
Identification of vitamin D (VDR) and retinoic X (RXR) receptor in normal and neoplastic human reproductive tissues (2013) (1)
P-68 The GH-IGF axis in glycogen storage disease type 1 (GSD): Evidence of different growth patterns and IGF levels in patients with GSD1 A and GSD1 B (2008) (1)
Might the response of cortisol to oral glucose tolerance test be used for the differential diagnosis of Cushing's syndrome and pseudo-Cushing's states? (2008) (1)
Characterization of R31C GNRH1 mutation in congenital hypogonadotropic hypogonadism (2013) (0)
Efficacy and safety of high doses of long-acting somatostatin analogues for treatment of well differentiated functioning neuroendocrine tumors (2006) (0)
EFFECTS OF PASIREOTIDE TREATMENT ON CARDIOMETABOLIC RISK IN PATIENTS WITH CUSHING’S DISEASE : AN ITALIAN, MULTICENTER STUDY (2017) (0)
In vitro effect of the somatostatin analogue BIM 23704 on cell cycle timecourse in an ovarian carcinoma cell line (2011) (0)
Endocrine system involvement in patients with RASopathies: A case series (2022) (0)
Early Left Ventricular Diastolic Dysfunction in Females with Chronic Hyperprolactinemia: A Doppler Echocardiographic Study (2023) (0)
Expression of mTOR and IGF2 and in vitro effects of mTOR inhibitor drugs on cell proliferation and cortisol production in human adrenocortical cancer cells (2010) (0)
Abstract #1403093: Absence of QT Prolongation Associated with Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Cushing Syndrome (2023) (0)
Microalbuminuria as well as insulin sensitivity are improved under octreotide-lar treatment in acromegalic patients (2006) (0)
Potential role of the adrenolitic drug mitotane in the treatment of hepatocarcinoma (HCC): effect on cell proliferation in HCC cell lines (2016) (0)
Treatment of acromegalic osteopathy in the real-life clinical practice: The baac (bone active drugs in acromegaly) multicenter study (2020) (0)
Management and outcome of pregnancies in women with adrenal insufficiency: experience from a retrospective European study (2019) (0)
Development of a disease-related QoL-questionnaire for Cushing's disease (2008) (0)
Sleep Disorders And Osas Risk in Patients with Prolactinoma: A Single Center Experience (2023) (0)
T-type calcium channel blockers inhibit hormone secretion and induce apoptotic cell death in a medullary thyroid cancer cell line (2011) (0)
Change in androgens and adrenal hormones during long-term osilodrostat treatment in patients with Cushing's disease: Results from the Phase III, prospective LINC 3 study (2022) (0)
P-16 Insulin/IGF system in human pituitary tumour: clinical and patho-biological insight (2008) (0)
Management of adjuvant mitotane therapy for adrenocortical carcinoma: a survey in Italy (2019) (0)
Berlin questionnaire and epworth sleepiness scale as screening tools of sleep apnea risk in patients with acromegaly: comparison of 144 patients and an age-and gender-matched health cohort (2022) (0)
The treatment with dual release hydrocortisone in patients with adrenal insufficiency: correlation between change of the evening cortisol exposure time profile and change in metabolic profile, depression status and quality of life (2017) (0)
Comorbidities and symptoms among patients with acromegaly in italy: a longitudinal retrospective chart review study (2018) (0)
Semen parameters in men with congenital adrenal hyperplasia (CAH) due to 21-hydroxilase deficiency (21-HD) (2012) (0)
Octreotide subcutaneous (s.c.) depot, a novel ready-to-use formulation, provides higher exposure and maintains response in patients with acromegaly and functioning neuroendocrine tumours (NETs) previously treated with long-acting octreotide: Results from a phase 2, open-label, multicentre, randomize (2017) (0)
Explorer R 31 C GNRH 1 mutation and congenital hypogonadotropic hypogonadism (2017) (0)
Abstract #497 Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome: Improvements in Clinical Signs and Symptoms, Patient-Reported Outcomes, and Associated Biochemical Markers in the Phase 3 Sonics Study (2019) (0)
Prolactin and prostate: an observational case-control study in men with prolactinoma under cabergoline treatment (2019) (0)
In the Phase III studies LINC 3 and LINC 4, osilodrostat was effective and well tolerated in patients of Asian and non-Asian origin with Cushing's disease (2023) (0)
17[beta]-hydroxysteroid dehydrogenase type 3 deficiency: a new case of a rare disease with an uncommon gene mutation (2011) (0)
Clinical Case 1 (2022) (0)
Subject Index Vol. 92, 2010 (2010) (0)
Dopamine receptor expression and function in the normal and pathological hypothalamus-pituitary-adrenal axis (2005) (0)
Clinical and biological parameters in 362 Klinefelter syndrome subjects: The KING experience (2016) (0)
Subject Index Vol. 92, 2010 (2010) (0)
Baseline characteristics and hormonal pattern in Klinefelter syndrome patients: first data from the Klinefelter ItaliaN Group (KING) (2018) (0)
Cardiac structure and function in patients with adrenal incidentaloma with and without subclinical Cushing's syndrome (2011) (0)
The medical treatment with pasireotide in Cushing's disease: an Italian multicenter experience based on [ldquo]Real Word Evidence[rdquo] (2016) (0)
The effect of the dopamine agonist cabergoline on insulin sensitivity in the skeletal muscle: an in vitro study in a mouse cell model demonstrating mediation by serotoninergic receptors (2018) (0)
Effect of the switch from conventional glucocorticoids to 'dual release hydrocortisone' in adult patients with primary and secondary adrenal insufficiency: a 6-month multicentre study (2015) (0)
The bidirectional relationship between testosterone and metabolic disorders: testosterone deficiency as an early marker of cardiovascular risk in young men (2022) (0)
Covid-19 in patients with hypocortisolism: clinical syndrome, disease duration and glucocorticoid replacement therapy (2022) (0)
Advances on complications and therapy of cushings syndrome (2021) (0)
Improved evening and nocturnal cortisol exposure time profile in patients with adrenal insufficiency treated with dual release hydrocortisone: correlation with improvement in metabolic profile (2016) (0)
Psychological distress in patients with hypocortisolism during mass quarantine for Covid-19 epidemic in Italy (2021) (0)
Morphostructural characterization of the testis in a large cohort of men living in highly polluted areas of Campania Region in south Italy: a focus on cadmium exposure (2022) (0)
Somatostatin receptor expression in hepatocellular carcinoma: correlation between sst2 expression and patients’ survival after octreotide LAR treatment (2006) (0)
Comparison of Metyrapone, OSilodrostat and KEToconazolE in the short-term thERapy of endogenous Cushing's syndrome: preliminary results of the MOSKETEER study (2023) (0)
Monthly pasireotide provides clinical benefit over 12 months in patients with Cushing's disease (2017) (0)
ENETS Newsletter Winter 2014 (2014) (0)
Combined effects of sirolimus and mitotane in the inhibition of growth in human adrenocortical carcinoma cells (2015) (0)
Effects of prolactin excess and treatment with cabergoline on bone mineral density and fracture risk in men (2023) (0)
Vitamin D pathway in non-functioning pituitary adenomas (2012) (0)
Use and effects of follicle-stimulating hormone (FSH) for idiopathic male infertility in Italy: results from a multicentre, observational, cohort, prospective, real world, clinical practice survey (2020) (0)
Psychopathology in Acromegaly - Real and Perceived. (2023) (0)
Medical Consequences of Long-term Treatment of Acromegaly (2010) (0)
Diabetes Mellitus Secondary to Cushing'S Disease or Acromegaly: a Single-Centre Experience (2023) (0)
Fertility 2015 (2015) (0)
Effects of short (12 months) and long (60 months) term treatment with cabergoline on metabolic syndrome and visceral adiposity index in patients with hyperprolactinemia (2013) (0)
Durability of response and gender-based analysis from the LINC3 trial of osilodrostat in the treatment in cushing’s disease (2020) (0)
Mapping of the current transition of care practice for patients with pituitary disease at Endo-ERN reference centers (2022) (0)
Characteristics, geographical distribution and age at diagnosis of patients with Klinefelter syndrome in Italy: a cohort study from the Klinefelter Italian Group (KING) (2019) (0)
ANew Somatostatin Analogue , Is Highly Effective in the Therapy of Growth Hormone / Prolactin-Secreting PituitaryAdenomas (2007) (0)
Testosterone replacement therapy outcomes in subjects with Klinefelter syndrome: preliminary results from a meta-analysis study (2019) (0)
The medical treatment of polycystic ovary syndrome: effects of inositol isomers and metformin on clinical, metabolic and hormonal profile (2022) (0)
Impact of Surgery or Medical Treatment with the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients with Cushing Syndrome (2023) (0)
Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience (2023) (0)
Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study (2022) (0)
The circadian rhythm of glucocorticoid administration entrains clock-controlled genes in blood mononuclear cells: a DREAM trial ancillary study (2018) (0)
Does clinical status correlate with the severity of GH deficiency (GHD) in adults (1998) (0)
Effects of short (6 months) and long (18 months) term treatment with GH-receptor antagonist pegvisomant (PEG) on rhythm disturbances in acromegaly (2011) (0)
Circulating miRNAs expression profile in in vitro muscle cell model exposed to cortisol excess (2019) (0)
Pooled analysis from two osilodrostat Phase III studies in Cushing's disease (LINC 3 and LINC 4): Clinical improvements according to urinary and late-night salivary cortisol levels (2023) (0)
Hormonal and metabolic effects of long-term cabergoline withdrawal in patients with hyperprolactinemia (2017) (0)
Dopamine receptor expression and dopamine agonist effectiveness in post-surgical persistent medullary thyroid cancer (2007) (0)
In vitro effect of dopastatins on hormone secretion in adrenal tumors (2010) (0)
Correction to: Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome (2020) (0)
Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma (2022) (0)
Sexual function in adrenal insufficiency: data from the DREAM trial (2019) (0)
First baseline data of the Klinefelter ItaliaN Group (KING) cohort: clinical features of adult with Klinefelter syndrome in Italy (2022) (0)
Pooled analysis of osilodrostat dosing across LINC 2, LINC 3 and LINC 4 in Cushing's disease (2023) (0)
Osilodrostat therapy improves physical manifestations of hypercortisolism in patients with cushing's disease: findings from the phase III LINC 3 study (2022) (0)
Correction to: Pegvisomant in acromegaly: an update (2017) (0)
Mutations of SOX2 gene: a novel heterozygous mutation and impact on congenital hypopituitarism (2013) (0)
The mTOR-pathway in normal and tumoral human adrenocortical tissues (2012) (0)
Thyroid diseases in the 'Land of Fires': results of a single center screening in Acerra (Naples) (2016) (0)
The severity of growth hormone deficiencyin adults is associated with impairment of bone status (1999) (0)
Association between biochemical control and comorbidities and symptoms among patients with acromegaly in Italy: a longitudinal retrospective chart review study (2018) (0)
Contents Vol. 98, 2013 (2014) (0)
Is arginine test a reliable tool for differential diagnosis of multiple system atrophy? (2010) (0)
First baseline data of the Klinefelter ItaliaN Group (KING) cohort: clinical features of adult with Klinefelter syndrome in Italy (2022) (0)
Effects of combined treatment with cabergoline and somatostatin analogues (SAA) on GH and IGF-I levels and tumor volume in patients with acromegaly not fully responsive to SAA (2007) (0)
Fertility in Acromegaly: a single center experience on female patients during active disease and after disease remission. (2021) (0)
Title Page / Table of Contents / Preface (2010) (0)
Title Page / Table of Contents / Preface (2010) (0)
Medicaltherapyforclinicallynon-functioning pituitary adenomas (2008) (0)
SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (2019) (0)
Comment on Azmahani et al. “Steroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditions” (2016) (0)
Safety of long-term combined therapy with somatostatin analogues and cabergoline (CAB) on cardiac valve in acromegaly: an echocardiography study (2009) (0)
Long-term pasireotide therapy: real life experience of a single referral center (2022) (0)
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY (2022) (0)
Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2) (2022) (0)
Real-world management of male idiopathic infertility in indication for FSH treatment: a multicenter, longitudinal, observational cohort study (open registry) (2019) (0)
Unmet needs on the current medical management of Cushing’s syndrome: results from a Delphi panel of Italian endocrinologists (2023) (0)
Does the age at onset of growth hormonedeficiency have an impact on cardiac performance (2000) (0)
Efficacy and safety of long-acting pasireotide (LA-PAS) in patients with uncontrolled acromegaly: Results from the prospective cohort of european observational acronis study (2020) (0)
[Chronic kidney disease: fertility and sexuality]. (2015) (0)
InfeCtious disease in patients with Adrenal endocRinOpathies: the ICARO prospective observational study (2019) (0)
Molecular events in a large series of advanced stage III-IV adrenocortical cancer: looking for new therapeutic options (2019) (0)
Evaluation of sexual function and psychological attitudes in adult women with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase Deficiency (21-HD) (2012) (0)
Effects of replication of the physiological and non-physiological cortisol rhythm on insulin sensitivity in muscle: a molecular in vitro analysis on synchronized muscular cells (2018) (0)
Cardiovascular Risk and Osteoporosis: Is There a Link? (2020) (0)
Reply: Letters to the Editors (2001) (0)
Osilodrostat maintains normalized urinary free cortisol levels in a majority of patients with Cushing's disease: Long-term results from an extension to the LINC-2 study (2017) (0)
Efficacy and safety of combined treatment with somatostatin analogues (SA) AND pegvisomant (PEG) in acromegalic patients resistant to SA (2010) (0)
SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM) (2019) (0)
Fertility and Environment: An Observational Study in Healthy Young Men from Different Areas of Campania Region (2016) (0)
Reversal effect of Vitamin D (VitD) on exosome-mediated everolimus resistance (EveR) in hepatocellular carcinoma (HCC) cell line: A molecular study (2020) (0)
Thyroid and growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis: A clinical and utrasonographic study in patients with acromegaly and hypopituitarism (1998) (0)
New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study. (2023) (0)
Reply (2001) (0)
An Open-Label Extension Study to Evaluate the Safety of Long-term Use of Relacorilant in Patients With Endogenous Cushing Syndrome (2023) (0)
Anti-Lipogenic effects of cabergoline: A molecular study on white adipocytes (2020) (0)
Erratum to: Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status (2014) (0)
Dopaminergic system and adipose tissue: in vitro effect of cabergoline on white, brown and beige adipogenesis and lipogenesis processes (2022) (0)
Cardiac structure and function in patients with adrenal incidentaloma: an echocardiographic study (2009) (0)
Pituitary Tumors, ACTH-Secreting (2014) (0)
Growth hormone deficiency in succesfully treated acromegalic patients is not protective from cardiac complications (2007) (0)
Psychological Impact of COVID-19 national lockdown meAsures on tRansgenDer people in Italy: The PICARD study (2021) (0)
Osilodrostat provides sustained control of urinary free cortisol in patients with Cushings disease: final results from a prospective, open-label study (LINC 2) (2021) (0)
Pregnancy outcomes following cabergoline treatment in hyperprolactinemic patients: an observational survey study (2012) (0)
CLINICAL CASE SEMINAR Recombinant Thyrotropin-Induced Orbital Uptake of [ 111 In-Diethylenetriamine-Pentacetic Acid- D Phe 1 ]Octreotide in a Patient with Inactive Graves’ Ophthalmopathy (2005) (0)
in the normal human thymus Age-related decrease of somatostatin receptor number (2006) (0)
The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian Scientific Societies, guidelines on the diagnosis and management of erectile dysfunction (2023) (0)
Erectile Dysfunction and Decreased Libido in Klinefelter Syndrome: A Prevalence Meta-Analysis and Meta-Regression Study. (2021) (0)
Trends of insulin-like growth factor 1, growth hormone, and biochemical control of patients with acromegaly in italy: a longitudinal retrospective chart review study (2018) (0)
Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool (2022) (0)
Uncontrolled Acromegaly, Diabetes Mellitus and Metabolic Syndrome are the Main Risk Factors of Colon Polyposis Recurrence in Patients with Acromegaly (2023) (0)
Effect of short- and long-term treatment with pasireotide on hemochrome in patients with Cushing's disease (2013) (0)
Selenium modulates apoptosis in thyroid follicular cells: characterization of molecular mechanisms (2016) (0)
Cabergoline counteracts adipose and skeletal muscle lipid accumulation through promoting oxidative pathway: an in vivo and in vitro preclinical study (2023) (0)
The benefits of pasireotide in patients with Cushing's disease are not restricted to patients with normalisation of UFC; results from a large, 12-month study (2013) (0)
Hypothalamic–Pituitary Axis Function (2020) (0)
The treatment with [lsquo]dual release[rsquo] hydrocortisone (DR-HC) in congenital adrenal hyperplasia: short-term (6 months) and long-term (12 months) follow-up after the switch from conventional glucocorticoids to DR-HC (2015) (0)
PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat (2022) (0)
PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study (2022) (0)
Epidemiology, histophatological characteristics and clinical manifestations of aggressive pituitary tumors, evaluated on the basis of KI-67 immunostaining: a single center experiense (2012) (0)
GH and GH antagonist B2036 effect on the immune system (2006) (0)
Psychological impact of Covid-19 national lockdown on patients with Cushing's syndrome in Italy: a case-control study (2022) (0)
Dual targeting of PIK3/AKT/mTOR and IGF1/KRAS/BRAF pathways in an in vitro model of ovarian cancer: strategies for cell proliferation control (2016) (0)
Abstract #1171307: Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome: a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study (2022) (0)
Genetic Heterogeneity in Adrenal Insufficiency (2019) (0)
Risk Factors Affecting Puberty: Environment, Obesity, and Lifestyles (2021) (0)
Dopamine D2 and somatostatin SST2 and SST5 receptor expression, function and regulation by glucocorticoids in medullary thyroid cancer cell line (2007) (0)
Efficacy, safety and metabolic impact of long-term pegvisomant therapy in acromegaly: results from a 10-year single center experience (2022) (0)
The treatment with glucocorticoids in congenital adrenal hyperplasia: short- and long-term effects of the switch from conventional glucocorticoids to 'dual release' hydrocortisone on metabolic and hormonal profile (2014) (0)
Acromegaly and Changes in Growth Parameters: A Focus on Cardiovascular, Metabolic, Respiratory Abnormalities, Malignancies, and Bone Alterations (2012) (0)
Male Hypogonadism Due to Disorders of the Pituitary and Suprasellar Region (2017) (0)
Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study (2022) (0)
Efficacy of testerone 2% gel replacement therapy on erectile function, muscle strenght and general wellbeing in men affected by normo-hypogonadotropic hypogonadism (2012) (0)
Pasireotide-induced hyperglycemia and efficacy of antidiabetic treatments in patients with acromegaly: Evaluation of two referral centers (2020) (0)
The spectrum of cardiac disease in patients with acromegaly: results from the SUM trial (2023) (0)
Development and validation of a questionnaire to evaluate health-related quality of life in patients with Cushings syndrome (2007) (0)
Association between the circadian rhythm and the inhibitory effect of glucocorticoids on browning of adipocytes (2020) (0)
Related articles (2013) (0)
Impact of urinary and late-night salivary cortisol levels on clinical signs of hypercortisolism and quality of life in patients with Cushing's disease treated with osilodrostat (2022) (0)
Cortisol rhythm in patients with adrenal insufficiency switched from conventional glucocorticoids to dual release hydrocortisone: Impact on metabolic profile (2020) (0)
The accuracy of the arginine growth hormone test in Parkinsonism (2008) (0)
Growth hormone, prolactin, and sexuality. (2012) (0)
EFFECT OF SWITCH FROM CONVENTIONAL GLUCOCORTICOIDS TO “DUAL RELEASE HYDROCORTISONE” (DR-HC) ON METABOLIC PROFILE AND QUALITY OF LIFE IN ADULT PATIENTS WITH SECONDARY ADRENAL INSUFFICIENCY (SAI): RESULTS OF THREE MONTHS FOLLOW-UP (2014) (0)
Impact of COVID-19 lockdown in patients with acromegaly: an Italian multicenter experience (2022) (0)
Determinants of the acromegalic cardiomyopathy: a prospective, controlled study in 205 patients (2007) (0)
Testis-Specific Genes Deregulation in the Testis of COVID-19 Patients: A Potential Driver of Spermatogenesis Disruption? (2022) (0)
Approach to the Patient with Prolactinoma. (2023) (0)
Management of mitotane for advanced adrenocortical carcinoma: a survey in Italy (2019) (0)
Pregnancy outcomes in women with classic and non-classic congenital adrenal hyperplasia (2023) (0)
Somatostatin receptor type 2 (SSTR2) expression regulation by miR-375 in a murine pituitary corticotroph tumor cell model (2023) (0)
Role of reversal of hypogonadism on the improvement of metabolic syndrome in male patients with hyperprolactinemia during chronic treatment with cabergoline (2013) (0)
A Delphi panel of Italian endocrinologists to define the unmet needs on the current management of Cushing's Syndrome (2022) (0)
Testosterone supplementation and bone parameters, a systematic review and meta-analysis study (2022) (0)
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms (2022) (0)
Cabergoline treatment in Cushing's disease: effect of cabergoline withdrawal in patients with normalized cortisol secretion after long-term treatment (2010) (0)
Bilateral inferior petrosal sinus sampling in cushing's syndrome: comparison between an old and a new technique in naples experience (2013) (0)
Cardiovascular risk after cessation of growth hormone treatment in people born small for gestational age. (2017) (0)
Association Between Biochemical Control and Comorbidities and Symptoms Among Patients with Acromegaly in Italy: Stratified Analyses by Age and Gender (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Rosario Pivonello?

Rosario Pivonello is affiliated with the following schools:

Rosario Pivonello's Academic­Influence.com Rankings

Rosario Pivonello's Degrees

Why Is Rosario Pivonello Influential?

Rosario Pivonello's Published Works

Published Works

What Schools Are Affiliated With Rosario Pivonello?

Rosario Pivonello's AcademicInfluence.com Rankings